P49 Efficacy and safety of mepolizumab in severe eosinophilic asthma: a real life study

Abstract

Background Mepolizumab has been recommended by NICE in 2017 for patients with severe eosinophilic asthma. Aim To investigate the efficacy and tolerability of mepolizumab treatment in severe eosinophilic asthma in a tertiary centre Methods All patients treated with mepolizumab from June 2017 to May 2018 in our centre and completed at least 6 months on treatment were included in this study. We compared baseline clinical outcomes (that included adjusted baseline exacerbation rate to 6 months) and the 6 months on treatment using standard statistics. Results In total, 39 patients were included in the analyses (29 female 74%, mean age=49 years (range 19–75). Comparing baseline to 6 months on treatment, there was significant reduction in the mean rescue oral corticosteroid (OCS) courses from 2.7±0.89 to 1.18±1.37 (p Conclusion This preliminary data showed significant reduction in OCS requiring exacerbations and mean maintenance prednisolone treatment following 6 months of mepolizumab treatment in patients with severe eosinophilic asthma. The treatment was generally well tolerated. The 12 months outcomes data will be available for presentation in the conference.